Efficacy of afatinib in the treatment of patients with non-small cell lung cancer and head and neck squamous cell carcinoma: a systematic review and meta-analysis
NNN Maarof, A Alsalahi, E Abdulmalek, S Fakurazi… - Cancers, 2021 - mdpi.com
… [22] was the first RCT that assessed the efficacy of afatinib monotherapy (second-line) for
progressed advanced NSCLC after the failure of the treatment with gefitinib or erlotinib. The …
progressed advanced NSCLC after the failure of the treatment with gefitinib or erlotinib. The …
… Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
… There is a high unmet need for patients with EGFR-mutant non–small cell lung cancer (…
their content, use or application and disclaims any responsibility for their application or use …
their content, use or application and disclaims any responsibility for their application or use …
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
… Therefore, the population in the present study was considered suitable for an evaluation
of gefitinib efficacy in patients with advanced NSCLC harboring an EGFR mutation. …
of gefitinib efficacy in patients with advanced NSCLC harboring an EGFR mutation. …
[HTML][HTML] Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J He, Z Huang, L Han, Y Gong… - … journal of oncology, 2021 - spandidos-publications.com
… , osimertinib has significantly improved their PFS and OS times compared with chemotherapy
(17). Furthermore, osimertinib has shown better efficacy than gefitinib or erlotinib in …
(17). Furthermore, osimertinib has shown better efficacy than gefitinib or erlotinib in …
[HTML][HTML] … the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced …
… ) gefitinib versus carboplatin/paclitaxel for Asian patients with advanced non-small-cell lung
cancer … mutation-positive NSCLC who received gefitinib versus patients with EGFR mutation-…
cancer … mutation-positive NSCLC who received gefitinib versus patients with EGFR mutation-…
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
YN Lamb - Targeted oncology, 2021 - Springer
… identified as key oncogenic drivers of non-small cell lung cancer (NSCLC). Osimertinib (…
OS analysis, median OS was 33.1 months with osimertinib versus 25.7 months with gefitinib …
OS analysis, median OS was 33.1 months with osimertinib versus 25.7 months with gefitinib …
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
… ranged from 0.2–2.2 months (range 15–29 Exon 20ins patients and 9–23 T790M patients)
[21, 23, 34], while the fourth study in which patients received either erlotinib or gefitinib …
[21, 23, 34], while the fourth study in which patients received either erlotinib or gefitinib …
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
… Lung cancer is the second most common cancer, with highest mortality (crude … cancers in
Hong Kong [1]. Almost 85%-90% of lung cancers are classified as non-small-cell lung cancer (…
Hong Kong [1]. Almost 85%-90% of lung cancers are classified as non-small-cell lung cancer (…
… for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer
BS Bogdanowicz, MA Hoch… - Journal of Oncology …, 2017 - journals.sagepub.com
… Gefitinib plus best supportive care in previously treated patients with refractory advanced
non-small-cell lung cancer… in several markets have supported their use for first-line therapy …
non-small-cell lung cancer… in several markets have supported their use for first-line therapy …
Adjuvant treatment with tyrosine kinase inhibitors in epidermal growth factor receptor mutated non-small-cell lung carcinoma patients, past, present and future
… , since 18 October 2016, restricted its use in lung cancer as a first line … The FDA approved
gefitinib for advanced NSCLC … , since 13 July 2015, it has been expanded for use as a first line …
gefitinib for advanced NSCLC … , since 13 July 2015, it has been expanded for use as a first line …